Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence

According to the Response Assessment in Neuro-Oncology criteria, new enhancement within the radiation field on contrast enhanced T1-weighted images within 12 weeks after completion of radiotherapy should not qualify for progressive disease, since up to 50% of these cases may be pseudoprogression (Ps...

Ausführliche Beschreibung